Shire Continues to Deliver Excellent Growth From Cor...(ling general and administrative ...),Health

Date:10/30/2009

ling, general and administrative (18.5) 267.3 Gain on sale of product rights - - Reorganization costs - - Integration and acquisition costs - - Depreciation 22.9 22.9 Total operating expenses - 533.4 Operating income - 133.6 Interest income - 0.2 Interest expense - (9.4) Other income, net - 7.0 Total other expense, net - (2.2) Income from continuing operations before income taxes and equity in earnings of equity method investees - 131.4 Income taxes - (42.8) Equity in earnings of equity method investees, net of tax - 0.6 Net income attributable to Shire plc - 89.2 Numerator for diluted EPS - 89.2 Weighted average number of shares (millions) - diluted - 548.3 Diluted earnings per ADS - 48.9c The following items are included in Adjustments: (a) Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($34.8 million) and tax effect of adjustment; (b) Acquisitions and integration activities Inventory fair value adjustment related to the acquisition of Jerini ($0.6 million); costs associated with the integration and acquisition of Jerini and EQUASYM from UCB ($6.2 million) and tax effect of adjustments; (c) Divestments, reorganizations and discontinued operations: Accelerated depreciation ($4.5 million) and reorganization costs ($2.0 million) for the transition of manufacturing from Owi
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease